Risk of malignancy including non-melanoma skin cancers with anti-tumour necrosis factor therapy in patients with rheumatoid arthritis: Meta-analysis of registries and systematic review of long-term extension studies

Clinical and Experimental Rheumatology

Volumn 30, Issue 5, 2012, Pages 756-764

  Le Blay, P ^a   Mouterde, G ^a   Barnetche, T ^b   Morel, J ^a   Combe, B ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Malignancy; Meta analysis; Rheumatoid arthritis; Systematic review; TNF antagonists

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CANCER RISK; DATA ANALYSIS; DRUG EXPOSURE; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; LUNG CANCER; MELANOMA; NON MELANOMA SKIN CANCER; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; RHEUMATOID ARTHRITIS; SKIN CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; HUMANS; INCIDENCE; ODDS RATIO; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870264325     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. NARVAEZ J, DÍAZ-TORNÉ C, RUIZ JM et al.: Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol 2011;29:991-7.
2. YAZICI Y, MONIZ REED D, KLEM C et al.: Greater remission rates in patients with early versus long-standing disease in biologicnaive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Clin Exp Rheumatol 2011;29:494-9.
3. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
4. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al:. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
5. VAN der HEIJDE D, KLARESKOG L, RODRIGUEZ-VALVERDE V et al:. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
6. FURST DE, SCHIFF MH, FLEISCHMANN RM et al:. Adalimumab, a fully human anti tumor necrosis factor-monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
7. VAN DE PUTTE LB, RAU R, BREEDVELD FC et al:. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003;62:1168-77.
8. WEINBLATT ME, KEYSTONE EC, FURST DE et al:. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
9. LIPSKY PE, VAN der HEIJDE DM, ST CLAIR EW et al:. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
10. MAINI RN, BREEDVELD FC, KALDEN JR et al:. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
11. MOOTS RJ, HARAOUI B, MATUCCI-CERINIC M et al:. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2011;29:26-34.
12. EMERY P, FLEISCHMANN RM, MORELAND LW et al.: Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, doubleblind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
13. KAY J, MATTESON EL, DASGUPTA B et al:. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75.
14. KEYSTONE E, HEIJDE D, MASON D JR. et al:. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
15. KEYSTONE EC, GENOVESE MC, KLARESKOG L et al:. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
16. SMOLEN J, LANDEWE RB, MEASE P et al:. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.
17. FLEISCHMANN R, VENCOVSKY J, VAN VOLLENHOVEN RF et al:. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11.
18. SMOLEN JS, KAY J, DOYLE MK et al:. GOAFTER study Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.
19. SMITTEN AL, SIMON TA, HOCHBERG MC et al:. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
20. BAECKLUND E, ILIADOU A, ASKLING J et al:. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
21. STRANGFELD A, HIERSE F, RAU R et al:. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
22. JOHANSSON M, TAN T, DE VISSER KE et al:. Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem 2007;101:918-26.
23. SGAGIAS MK, KASID A, DANFORTH DN JR.: Interleukin-1 alpha and tumor necrosis factor-alpha (TNF alpha) inhibit growth and induce TNF messenger RNA in MCF-7 human breast cancer cells. Mol Endocrinol 1991;5:1740-7.
24. BONGARTZ T, SUTTON AJ, SWEETING MJ et al:. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
25. COSTENBADER KH, GLASS R, CUI J et al:. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis [letter] JAMA 2006;296:2201-4.
26. OKADA SK, SIEGEL JN: Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 2006;296:2201-2; author reply 2203-4.
27. BONGARTZ T, WARREN FC, MINES D et al:. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data metaanalysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83.
28. LEOMBRUNO JP, EINARSON TR, KEYSTONE EC: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
29. GEBOREK P, BLADSTRÖM A, TURESSON C et al:. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703.
30. WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effects of methotrexate and anti-tumor necrosis factor therapy in 18 572 patients. Arthritis Rheum 2004;50:1740-51.
31. WOLFE F, MICHAUD K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.
32. SETOGUCHI S, SOLOMON DH, WEINBLATT ME et al:. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757-64.
33. GIBOFSKY A, PALMER W, KEYSTONE EC et al:. Safety profiles of Disease-Modifying Anti-Rheumatic Drugs and Biologies in Patients with Rheumatoid Arthritis: Observation from the RADIUS Registry [Abstract]. Arthritis Rheum 2009;60 (Suppl.) 10.
34. ASKLING J, VAN VOLLENHOVEN RF, GRANATH F et al:. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-9.
35. CARMONA L, DESCALZO MA, PEREZ-PAMPIN E et al:. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66:880-5.
36. MERCER LK, GALLOWAY JB, LUNT M et al:. The Influence of Anti-TNF Therapy Upon Incidence of Non-Melanoma Skin Cancer (NMSC) in Patients with Rheumatoid Arthritis (RA): Results From the BSR Biologies Register (BSRBR) [Abstract]. Arthritis Rheum 2009;60 (Suppl.) 10:2062.
37. ASKLING J, ON BEHALF OF THE ARTIS STUDY GROUP: Anti-TNF therapy and risk of skin cancer, data from the Swedish ARTIS registry 1998-2006. [Abstract] EULAR 2009 FRI0201
38. GREENBERG J, STRAND V, KEYSTONE E et al.: TNF inhibitors (TNF-I) and risk of malignancy in 8, 072 RA patients followed over 15, 495 patient years. [Abstract] ACR 2007 282.
39. PAY S: Risk of cancer in Turkish patients after treatment with TNF antagonists. Rheumatology (Oxford) 2008;47:548-9.
40. ASKLING J, FORED CM, BRANDT L et al:. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6.
41. KLARESKOG L, COHEN SB, KALDEN JR et al.: Safety and efficacy of up to 10 continuous years of etanercept therapy in patients with rheumatoid arthritis in north America and Europe. Ann Rheum Dis 2009;68(Suppl. 3):424.
42. MORELAND LW, WEINBLATT ME, KEYSTONE EC et al.: Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61.
43. KLARESKOG L, GAUBITZ M, RODRIGUEZVALVERDE V et al.: A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 2006;65:1578-84.
44. BURMESTER GR, MEASE P, DIJKMANS BA et al.: Adalimumab safety and mortality rates from global clinical trials of six immunemediated inflammatory diseases. Ann Rheum Dis 2009;68:1863-9.
45. LEBWOHL M, BLUM R, BERKOWITZ E et al.: No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 2005;141:861-4.
46. BUCHBINDER R, BARBER M, HEUZENROEDER L et al:. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008;59:794-9.
47. PINCUS T: The clinical efficacy of 3 mg/day prednisone in patients with rheumatoid arthritis: evidence from a randomized, doubleblind, placebo-controlled withdrawal clinical trial. Clin Exp Rheumatol 2011;29(Suppl. 68):S73-6.
48. BOERS M: The COBRA trial 20 years later. Clin Exp Rheumatol 2011;29(Suppl. 68):S46-51.
49. KLARESKOG L, GAUBITZ M, RODRÍGUEZ-VALVERDE V, MALAISE M, DOUGADOS M, WAJDULA J: Etanercept Study 301 Investigators. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238-47.
50. DIXON WG, WATSON KD, LUNT M et al:. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2010 (Hoboken); 62:755-63.
51. CHAKRAVARTY EF, MICHAUD K, WOLFE F: Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-5.
52. KRATHEN M, GOTTLIEB A, MEASE P: Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis. J Rheumatol 2010;37:11.
53. ASKLING J, FAHRBACH K, NORDSTROM B et al:. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-130.